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Summary
The development of safe methods for inducing donor-specific tolerance across xenogeneic barriers
could potentially relieve the critical shortage of allograft donors that currently limits the applicability
of organ transplantation. We report here that such tolerance can be induced in a xenogeneic
combination (rat - mouse) using a nonmyeloablative and nonlethal preparative regimen. Successful
induction of chimerism and donor-specific transplantation tolerance required pretreatment of
recipients with monoclonal antibodies (mAbs) against NK1.1, Thy-1.2, CD4 and CD8, followed
by administration of 3 Gy whole body radiation (WBI), 7 Gy thymic irradiation, and infusion
of T cell-depleted rat bone marrow cells (BMC). Rat cells appeared among peripheral blood
lymphocytes (PBL) of such recipients by 2-3 wk, and rat T cells by 2-5 wk following bone
marrow transplantation (BMT). Donor-type rat skin grafts placed 4 mo after BMT were accepted,
while simultaneously placed non-donor-type rat skin grafts were promptly rejected. In addition
to its clinical potential, the ability to induce donor-specific tolerance across xenogeneic barriers
using such a nonlethal preparative regimen provides a valuable model for the study of mechanisms
of xenogeneic transplantation tolerance.
A
n inadequate supply of allogeneic donors has become
the major limitation to the rapidly advancing field of
clinical organ transplantation. Transplantation oforgans across
species barriers could potentially provide a solution to this
problem. Although the use of lethal irradiation and bone
marrow transplantation (BMT)' has been shown to induce
transplantation tolerance across xenogeneicbarriers in animal
models (1-5), the clinical applicability of such an approach
is limited by the toxicity of the preparative regimen. It will
therefore be essential to develop less toxic methods for in-
ducing xenogeneic chimerism ifthis approach is to be useful
clinically. Previous work from this laboratory has demon-
strated that chimerism and transplantation tolerance can be
induced across complete allogeneic MHC barriers in mice
using a nonlethal preparative regimen, in which anti-CD4
and anti-CD8 mAbs are used instead of lethal irradiation to
eliminate mature T cells from the host. Following this mAb
treatment, relativelynontoxic whole body irradiation (WBI)
at 3 Gy plus 7 Gy thymic irradiation were sufficient to permit
'Abbreviations used in this paper: BMC, bone marrow cells; BMT,
bone marrow transplantation; FCM, flow cytometry; LCA, leukocyte
common antigen; TCD, T cell-depleted; TI, thymic irradiation;
TRA, Texas red streptavidin; WBI, whole-body irradiation.
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engraftment of allogeneic bone marrow (6). Attempts to ex-
tend this model to a xenogeneic rat/mouse strain combina-
tion were not successful using the same nonlethal prepara-
tive regimen that was effective in allogeneic combinations.
However, addition of antibodies against host NK cells and Thy-
1+ cells to the preparative regimen led to successful induc-
tion ofxenogeneicchimerism and specific transplantation toler-
ance. Although the level ofchimerism diminished gradually
over time, specific acceptance ofdonor skin grafts was durable,
indicating that specific transplantation tolerance across a
xenogeneic barrier can be induced using a nonlethal prepara-
tive regimen.
Materials and Methods
Animals.
￿
Male C57BL/10SnJ (B10) and B10.D2/nSn (B10.D2)
mice were purchased from The Jackson Laboratory, Bar Harbor,
ME. Male Wistar-Furth (WF) and Fisher 344 (F344) rats were
purchased from Frederick Cancer Research Facility, Frederick, MD.
All animals were maintained in a specific pathogen-free facility.
Conditioning andBMT .
￿
B10 recipients (12-20 wk old) received
mAbs intraperitoneally on days -6 and -1. Doses of each mAb
were as follows: 0.1 ml of GK1.5 (7) (rat anti-mouse CD4) ascites
(cytotoxic titer 1 :64,000); 0.1 ml of2.43 (8) (rat anti-mouse CD8)
ascites (cytotoxic titer 1 :80,000); 500 p.g 30-H12 (9) (rat anti-mouse
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195-202Thy-1.2), purified from ascites by 50% ammonium sulfate precipi-
tation followed by filtration on an Ultragel AcA 34 column and;
400 Fcg of PK136 (murine anti-NK1.1 mAb [10]) 50% ammonium
sulfate precipitated. On day 0, 3 Gy WBI and 7 Gy selective thymic
irradiation (TI) were administered to mAb-treated animals, as pre-
viously described (6). Bone marrow cells (BMC) were administered
intravenously on the same day, as described (6). Animals received
60 x 106 rat (F344) BMC, which had been T cell-depleted (TCD)
using mAb R1-3B3 (11) (anti-CD5) followed by two cycles of rabbit
complement (Cedarlane Laboratories, Ontario, Canada). Control
animals received 15 x 106 allogeneic B10.D2 BMC, which were
T cell-depleted using anti-CD4 plus anti-CD8 plus anti Thy-1.2
mAbs and rabbit complement, as described (12). Depletion of rat
marrow was evaluated by flow cytometry (FCM) analysis after
staining with fluoresceinated anti-CD2 (OX-34; Bioproducts for
Science, Indianapolis, IN). Fewer than 0.7% CD2+ T cells re-
mained after depletion.
Phenotyping ofBMTRecipients.
￿
Rat PBL, thymocyte and BMC
chimerism were evaluated by staining with FITC-conjugated mAb
OX-1 (Bioproducts for Science), which recognizes a rat leukocyte
common antigen (LCA) expressed on all rat leukocytes. Rat T cells
were detected using FITC-conjugated anti-rat CD5 mAb OX-19
(Bioproducts for Science). In control recipients ofallogeneicBMT,
donor-type chimerism was testedby staining with biotinylated mAb
34-2-12 (anti-Dd) (13). For detection of host-type cells, biotinylated
anti-Kb mAb 5F1 (14) was used. For detection of murine T cells,
biotinylated antiThy-1.2 mAb (Becton Dickinson & Co., Moun-
tain View, CA) was used. Expression of Thy-1.1, but not of the
Thy-1.2 allele, has been detected on some types of rat cells (15) .
For red fluorescence (detected on FACS II), incubation with bio-
tinylated antibody was followed by incubation with Texas red strep-
tavidin (TRA; Bethesda Research Laboratories, Bethesda, MD) .
For orange fluorescence (detected on FACSCAN), incubation with
biotinylated antibody was followed by incubation with phycoery-
thrin-streptavidin (PEA). FITC-conjugated and biotinylated mAb
Leu-4 (Becton Dickinson & Co.) were used as nonstaining irrele-
vant antibodies for green and red or orange staining, respectively.
FCM Analysis.
￿
Two-color FCM was performed as described
(16) using a FACS II (Becton Dickinson) or a FACSCAN (Becton
Dickinson). Contour plots were generated as described (17). For
calculation from contour plots of the percentage of cells staining
with FITC-labeled mAbs, the percentage of cells in each green-
positive rectangle after staining with Leu-4-FITC was subtracted
from the percentage of cells staining with the FITC-conjugated
test antibody in the same rectangle; for determination of the per-
centage of cells staining with biotinylated mAbs, the percentage
ofcells in each red or orange-positive rectangle after staining with
Leu-4-biotin was subtracted from the percentage of cells staining
with the biotinylated test antibody in the same rectangle.
Skin Grafting.
￿
Full thickness skin grafting was performed ac-
cording to a modification of the method of Billingham, as described
(18). Grafts were evaluated daily, and were consideredto be rejected
when less than 10% of the original graft was detectable.
Statistical Analysis.
￿
Skin graft survival probability was deter-
mined using the censored data technique of Kaplan-Meier, and
statistical significance was determined using the method of Wil-
coxon and Breslow. All statistical results are expressed as P values,
and values less than 0.05 are considered to be significant.
Results
mAb Requirements for Induction of Mixed Rat/Mouse
Chimerism.
￿
Groups of recipient B10 mice were prepared as
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indicated in Table 1. Xenogeneic PBL chimerism was evalu-
ated 2-3 wk following BMT by staining with mAb recog-
nizing all rat leukocytes (OX-1) or rat T cells (OX-19). Rat
PBL chimerism was not detectable in any of 12 animals
pretreated with anti-CD4 plus anti-CD8 mAbs (Table 1, Exp.
1) . In contrast, this regimen permitted the development of
allogeneic chimerism in 9 of 12 control recipients of B10.D2
BMC in the same experiment (Table 1, Exp. 1), similar to
previous results (6).
Since NK cells can mediate alloresistance (19-23), we con-
sidered the possibility that host NK cells might be preventing
engraftment of xenogeneic marrow. We therefore examined
the effect of depleting host NK cells by adding anti-NK1.1
mAb to the preparative regimen. PBL chimerism was pro-
duced in two of six such recipients (Table 1, Exp. 2, Group
3). This result, however, was not significantly different from
that achieved in animals pretreated with anti-CD4 plus anti-
CD8 alone in this experiment, in which one of four animals
demonstrated PBL chimerism 2-3 wk after BMT (Table 1,
Exp. 2, Group 1) . Chimerism was not achieved in any of
six animals pretreated with anti-NK1.1 mAb without anti-
CD4 or anti-CD8 (data not shown) .
Since our regimen of treatment with anti-CD4 plus anti-
CD8 mAbs is associated with persistence of a small residual
population of Thy-1+ CD4- , CD8- cells (Sharabi, Y., and
D. H. Sachs, unpublished data), we evaluated the effect on
xenogeneic marrow engraftment of eliminating this popula-
tion by pre-treating recipients with large amounts of anti-
Thy-1.2 mAb. As shown in Table 1 (Exp. 2, Group 2), sig-
nificant, but low (6-10% of PBL) levels of rat PBL chimerism
were detectable in six of six recipients pretreated with anti-
Thy-1.2 mAb in addition to anti-CD4 plus anti-CD8 .
In the same experiment, we also evaluated the effect of
combined pretreatment with antiThy-1.2, anti-NK1.l, anti-
C134, plus anti-CD8 mAbs on engraftment of rat BMC. As
is shown in Table 1 (Exp. 2, Group 4), pretreatment with
this combination of mAbs was associated with engraftment
of rat cells in 10 of 10 recipients. The levels ofrat cell repopu-
lation at this early time point (2-3 wk after BMT) were ap-
proximately twice as high as those in animals treated with
anti-Thy-1.2, anti-CD4 and anti-CD8 (Group 2). The time
course of the two-color FCM profile produced by PBL from
a representative animal in this group is shown in Fig. 1. It
was apparent from these data that optimal early engraftment
of rat marrow was attained using a combination of mAbs
against CD4, CD8, Thy-1.2, and NK1. Similar results were
obtained in a repeat experiment (data not shown) .
Time Course ofRat PBL Repopulation.
￿
The percentage of
rat PBL repopulation in recipients of various mAb pretreat-
ments was further evaluated at later time points. As shown
in Fig. 2, the percentage of rat cells declined gradually over
time in all chimeric recipients originally pretreated with anti-
CD4, anti-CD8, plus antiThy-1.2, with or without anti-
NK1.1 mAb. By -6 mo after BMT, only one of five survi-
vors of the three mAb pretreatment and two of six survivors
of the four mAb regimen contained >1% rat PBL (Fig. 2).
Of the two chimeric animals pretreated with anti-CD4, anti-
CD8, and anti-NK1.1 mAbs, one animal lost its chimerismTable 1 .
￿
Engraftment of TCD Rat BMC in Mice Prepared Using a Nonlethal Regimen
" B10 recipients were injected with mAbs on day - 6 and day -1, followed by administration of 300 rad WBI, 700 rad TI, and BM cells
on day 0.
t 15 x 106 MOM BM, T cell depleted with anti-CD4 (GK1.5 15), anti-CD8 (2.43 16) and anti-Thy-1.2 (30-H12 17 ) plus complement or 60
x 10 6 F344 BM, T cell depleted with anti-CD5 (R1-3B3 1s) and complement .
5 Xenochimerism was detected by flow cytometry analysis after staining PBL with fluoresceinated anti-rat LCA (OX-1) or with irrelevant
mAb, fluoresceinated anti-human CD3 (Leu-4) . Percent rat cells was calculated by the formula : Percent rat cells = 100 x {[(% OX-1+ -
% Leu-4± cells in transplanted animal) - (% OX-1+ - % Leu-4+ cells in B10 control)]/[(% OX-1+ - % Leu-4+) in rat control]). Al-
lochimerism was tested by flow cytometry after staining donor cells with anti-Dd (34-2-1219) mAb and percent donor cells was calculated
by a similar formula .
11 One animal in this group showed exceptionally high levels of rat cell engraftment .
by 35 d after BMT, whereas rat cells became undetectable
in the PBL of the other animal between 90 and 120 d after
BMT (data not shown) .
In most chimeric animals in all groups, rat T cells were
not detected among PBL tested 2-3 wk afterBMT Among
PBL of all mice pretreated with anti-CD4, anti-CD8, anti-
NK1.1, and antiThy-1.2, rat T cells appeared by 5 wk after
BMT, and their percentage continued to increase,until 7 wk
in most animals (Table 2) . The presence of such T cells in
one representative animal is illustrated in Fig. 2 . By day 90,
the percentage of rat T cells had declined significantly in all
animals, and continued to decline in parallel with the general
decline of rat PBL chimerism (Table 2, Fig. 2) . Among six
chimeric animals pretreated with antiThy-1.2, anti-CD4, and
anti-CD8 mAbs without anti-NKI .1, rat T cells appeared
among PBL of three mice, and followed a similar time course
to that observed in animals pretreated with all four mAbs
(Table 2) . Rat'T cells appeared with a similar time course
among PBL of one of two chimeric animals pretreated with
anti-CD4, anti-CD8, plus anti-NK1.1mAbs (data not shown) .
Most animals appeared healthy for the duration of the ex-
periment, with no clinical evidence for GVHD. The only
exceptional animal was the one outlier recipient in group 4
(Table 1) which demonstrated 66% rat PBL reconstitution
by 2 wk after BMT This animal appeared wasted and ill,
and died 7 to 13 wk afterBMT This was also the only an-
imal in which ratT cells were detectable by 2 wk afterBMT,
consistent with the possibility that GVHD had developed
in this recipient .
In general, murine T cells began to appear at the same
time as rat T cells, i.e., between 3 and 5 wk after BMT (data
not shown) .
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Rat Cell Repopulation ofOther Lymphoid Compartments.
￿
To
evaluate engraftment of rat cells in lymphoid organs other
than PBL, one animal was killed 45 d afterBMT, and staining
of splenocytes, thymocytes, and BMC was performed . As
shown in Fig . 3, OX-1+ rat leukocytes were detectable
among thymocytes and BMC ; rat cells were also detectable
among splenocytes (data not shown) . Only a fraction of the
OX-1+ rat cells in peripheral organs stained with the 0X-
19 T cell marker, in proportion to the overall percentage of
T cells in each organ (see normal rat and mouse controls,
Fig. 3) ; the percentage of OX-19+ cells among thymocytes
was approximately equal to the total percentage of OX-1+
cells in this organ (Fig. 3) .
Induction ofTransplantation Tolerance .
￿
To determine whether
or not recipients were tolerant ofdonor antigens, donor-type
F344 rat skin grafts were placed on all survivors -120 d after
BMT The results, shown in Fig . 4 (top), demonstrate that
animals pre-treated with either anti-CD4 plus anti-CD8 alone
(n = 4), or with anti-NK1 .1 mAb in addition to anti-CD4
plus anti-CD8 (n = 6), rejected F344 skin grafts with a similar
time course to that demonstrated by normal B10 mice (n =
4) (p > 0.05) . Thus, tolerance was not induced in these mice .
In contrast, animals originally pretreated with antiThy-1.2,
anti-CD4, plus anti-CD8 mAbs (n = 5) demonstrated sig-
nificant prolongation of donor skin graft survival (p = 0.01) .
Skin graft rejection in this group followed a chronic pattern
with signs of inflammation apparent by 50 d after grafting
in all animals, leading to rejection by 82 d (205 d afterBMT) .
The most striking prolongation of F344 graft survival was
observed among recipients originally pretreated with all four
mAbs (antiThy1.2, anti-NK1.1, anti-CD4, anti-CD8) . Five
of six animals in this group retained F344 skin grafts in ex-
Exp . Group mAb treatment" Donor#
Fraction of chimeric
(percent donor
2-3 wk
animalss
cells)
5 wk
1 1 Anti-CD4 + anti-CD8 B10.D2 9/12 (14-81)
2 Anti-CD4 + anti-CD8 F344 0/12
2 1 Anti-CD4 + anti-CD8 F344 1/4 (3) 0/4
2 Anti-CD4 + anti-CD8 + anti-Thy-1 .2 F344 6/6 (6-10) 5/6 (1-9)
3 Anti-CD4 + anti-CD8 + anti-NKI .1 F344 2/6 (3-14) 1/6 (4)
4 Anti-CD4 + anti-CD8 + anti-Thy-1 .2 + anti-NK1 .1 F344 10/10 (9-24, 660) 9/9 (1-9, 770)Figure 1 .
￿
Development of xenochimerism in B10 mice pretreated
with anti-CD4, anti-CD8, antiThy-1 .2 plus anti-NK1.1 mAbs followed
by 300 rad WBI, 700 rad TI, and infusion of 60 x 106 TCD rat
BM . Two-color immunofluorescence profiles of PBL from B10 control
(a and 6), rat control (c and d), and a typical chimera (e-h) . (Top)
Contour plots after staining with fluoresceinated anti-rat LCA (OX-1)
mAb, which stains all rat leukocytes (green fluorescence, horizontal
axis) and biotinylated anti-Kb (5F1) mAb plus TRA, staining all cells
cellent condition for more than 110 d . In several animals, epi-
sodes of mild inflammation, presumably due to rejection epi-
sodes, appeared and subsequently resolved . The prolongation
of skin graft survival in this group was highly significant com-
pared with B10 controls (p = 0.002) .
There was not a complete correlation between skin graft
acceptance and PBL chimerism at the time of skin grafting .
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of B10 origin (red fluorescence, vertical axis) . (Bottom) Contour plots
after staining with fluoresceinated anti-CD5 (OX-19), which stains
rat T cells (green fluorescence, horizontal axis), and biotinylated anti-
Thy-1.2 plus TRA, staining murine T cells (red fluorescence, vertical
axis) . Percentages of cells in each rectangle were determined by sub-
traction of background staining, as described in Materials and
Methods .
For example, one animal originally pretreated with all four
mAbs no longer displayed significant PBLchimerism by day
90 after BMT, but retained its F344 skin graft in perfect con-
dition by day 220 afterBMT Conversely, one animal pretreated
with anti Thy-1.2, anti-CD4 plus anti-CD8 mAbs still demon-
strated rat PBL chimerism by 183 d after BMT, but chroni-
cally rejected its F344 skin graft, with complete rejection by
Figure 2 .
￿
Rat PBL chimerism at various times
following BMT Percentages of OXl' cells among
PBL of individual animals were determined by
FCM, as described in Materials and Methods, and
calculations were performed as described in the
legend to Table 1 . Each type of bar represents a
single animal at the different time points shown
after BMT (horizontal axis) . (Left) OXV cells
among PBL of B10 mice pretreated with anti-CD4,
anti-CD8, plus anti-Thy-1.2 mAbs ; (right) OXl
cells among PBL of B10 mice pretreated with anti-
CD4, anti-CD8, antiThy-1.2, plus anti-NK1 .1
mAbs . All animals received 7 Gy TI plus 3 Gy
WBI before infusion of 60 x 10 6 TCD rat BMC .Figure 3.
￿
Xenogeneic engraftment in thymus and bone marrow.
Two-color immunofluorescence profiles of thymocytes (aj) and BMC
(g-o from B10 control (a, d, g, and J), rat control (b, e, h, and k)
and a typical chimera (c, f, i, and >) prepared by the modified non-
lethal regimen, 45 d after BMT Data presented as contour plots after
staining with fluoresceinated OX1 (anti-rat LCA, staining all rat leu-
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" Determined using anti-CD5 mAb OX19 as described in Materials and Methods .
t Weeks after BMT .
5 Days after skin grafting. Grafting with F344 rat skin was performed -18 wk after BMT.
n Animal died 74 d after skin grafting with intact graft .
kocytes) (a-c and g-i), or with fluoresceinated OX19 (anti-rat CD5,
staining ratT cells) (d-f and j-1) (green fluorescence, horizontal axis)
and biotinylated anti-Kb mAb plus TRA (a-c and g-i), staining all
cells of mouse origin or biotinylated antiThy-1.2 mAb plus TRA
(d-f and.-l), staining mouse T cells (red fluorescence, vertical axis) .
Table 2. Rat T Cell Repopulation in PBL of Mice Prepared with a Nonlethal Regimen
MAb pretreatment Animal
Rat
Weeks# : 2-3
T cells
5
in PBL"
7 26
Skin graft
survival
ds
Anti-CD4 + anti-CD8 + anti-Thy-1 .2 1 0.4 5.8 4.7 1 .2 74
2 0 0 0 0 18
3 0 1 .3 0.1 0 82
4 0.1 0 0 0 8
5 0 2.0 3.4 0.7 74
Anti-CD4 + Anti-CD8 + anti-Thy-1 .2 + anti-NKI .1 1 0.2 3 .3 4.1 1 .3 >110
2 0.3 3.8 5.8 0.8 28
3 0.8 3.9 5.8 0.2 >7411
4 0.2 3.0 3.0 0.1 >110
5 0.3 1 .7 3.8 0.1 >110
6 0 1 .8 0.3 0 >110Figure 4 .
￿
Survival of donor-type (top, F344) and non-donor-type
(bottom, WF) rat skin grafts placed 123 d after BMT on recipients of
7 Gy TI, 3 Gy WBI, and 60 x 106 TCD F344 BMC, following
pretreatment with : (- -) anti-CD4 plus anti-CD8 mAbs; ( . . . . )
anti-CD4, anti-CD8, plus anti-NK1 .1 mAbs; (---) anti-CD4, anti-
CD8, plus antiThy-1 .2 mAbs ; (-) anti-CD4, anti-CD8, antiThy-
1.2, plus anti-NK1 .1 mAbs. (- -) Skin graft survival on untreated
B10 controls.
197 d afterBMT Among animals pretreated with antiThy-
1.2, anti-CD4, and anti-CD8 mAbs, the three animals demon-
strating marked prolongation of F344 skin graft survival were
the only three animals in this group in which rat T cells ap-
peared among PBL at any time (see Table 2) .
Specificity ofTransplantation Tolerance.
￿
To determine whether
or not tolerance to rat skin grafts was donor-specific, a WF,
non-donor-type rat skin graft was placed on the opposite side
of the thorax at the same time as grafting with F344 (donor-
type) skin . As shown in Fig. 4 (bottom panel), these grafts
were promptly rejected by all groups . Thus, the transplanta-
tion tolerance induced in these animals was specific for the
rat strain of the donor marrow.
Discussion
Due to the inadequate supply of allogeneic organ donors,
it will be essential to overcome xenogeneic transplantation
barriers if transplantation is to reach its full potential as a
therapeutic modality . While the ability to induce donor-
specific tolerance, obviating the need for chronic immunosup-
pression, would be most desirable, such an approach is ham-
pered by the fact that currently available regimens for inducing
allogeneic chimerism are myeloablative and are therefore ex-
tremely toxic . We have recently described a method for
producing allogeneic chimerism and transplantation tolerance
across MHC barriers that specifically targets mature host T
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cells for elimination, and that therefore has minimal myelotox-
icity (6) . In the present report, we demonstrate that a
modification of this regimen can be used to induce specific
transplantation tolerance across xenogeneic barriers . This
modification involves administration of antibodies against
NK1.1 and Thy-1.2 antigens in addition to the anti-CD4 plus
anti-CD8 mAbs used for the induction of allogeneic toler-
ance. These results imply that, in contrast to alloengraftment,
more exhaustive depletion of T cells and depletion of NK
cells may be necessary to achieve xenoengraftment . Since some
NK cells, including those that are activated (24), as well as
NK cell precursors (25), express the Thy-1 marker (24), and
a small population of NK cells do not express NK1 .1 (10),
it is possible that both anti Thy-1.2 and anti-NK1 .1 are re-
quired for adequate elimination ofNK cells . Lymphokine ac-
tivated killer (LAK) cells (24), which likewise express Thy-1,
may also be involved in xenoresistance . NK cells have been
shown to resist engraftment of allogeneicBM grafts in mice
(19-23), and might play an even stronger role in resisting
xenoengraftment . Our data would also be consistent with
a role for Thy-1+ CD4- , CD8- T cells, such as those that
express a TCR-y/b on their surface, in preventing engraft-
ment of xenogeneic marrow.
Although initial levels of chimerism were significantly
greater among animals pretreated with anti-NK1.1, anti Thy-
1.2, anti-CD4, and anti-CD8 mAbs, than among recipients
of a similar pretreatment regimen without anti-NK1 .1, these
differences disappeared with time, so that the levels of total
PBL and T cell chimerism were not noticeably different be-
tween the two groups by the time of skin grafting at 120 d
after BMT The eventual rejection of donor skin grafts by
chimeric animals originally pre-treated with anti Thy-1.2, anti-
CD4, plus anti-CD8mAbs without anti-NK1 .1 might there-
fore reflect the activity of persistent NK1.1' xenoresistant
cells that were not ablated by the preparative regimen . Since
the addition of anti-NK1 .1 antibody to the pretreatment
regimen eliminated such resistance without prolonging the
duration of chimerism, this result suggests that nontolerant
NK1.1' cells may participate directly in xenogeneic skin
graft rejection, or alternatively, may prevent the development
of T cell tolerance without preventing initial engraftment
ofxenogeneic marrow . It has recently been demonstrated that
NK1.1+ TCR-a//3-bearing cells exist in the bone marrow
of normal mice (Sykes,M ., manuscript submitted for publi-
cation), and Yankelevitch et al . have recently demonstrated
a role for cells with this phenotype in the rejection of al-
logeneic bone marrow grafts (20) ; such cells might be capable
of specifically recognizing xenoantigens and participating in
skin graft rejection .
The imperfect correlation between long-term chimerism
and transplantation tolerance is as yet unexplained ; however,
the minimal requirements for tolerance induction clearly in-
clude both adequate ablation of host resistance and condi-
tions permitting the early development of chimerism . It is
possible that, among animals pretreated with all four mAbs,
chimerism persists indefinitely in organs that may be critical
to the maintenance of tolerance, such as the thymus, similarto results in neonatally tolerized mice (26). Alternatively, a
tolerant T cell repertoire might be formed early after trans-
plantation, and may persist even after rat cell chimerism has
disappeared. While evidence suggests that clonal deletion of
T cells reactive against histocompatibility antigens borne on
BM-derived elements occurs in the thymus, the type of BM-
derived cell responsible for such clonal deletion has not been
defined (27, 28) . The failure to induce tolerance in the ab-
sence of persistent peripheral lymphoid chimerism in some
allogeneic BMT models (29-31) might reflect incompleteab-
lation of host immunity rather than a need for persistent
chimerism per se in the maintenance of tolerance.
Among animals pretreated with antiThy-1, anti-CD4, plus
anti-CD8 mAbs without anti-NK1.1, only those in which
rat T cells were detectable among PBL showed marked prolon-
gation of donor skin graft survival. This result is consistent
with the possibility that donor cells in the thymus are in-
volved in the production of a tolerant T cell repertoire, but
that residual xenoresistant cells (possibly NK cells) rejected
the skin grafts.
It is possible that donor rat skin grafts on animals pretreated
with all four mAbs will be rejected very late after transplan-
tation. In fact, it has previously been hypothesized that the
expression of skin-specific antigens on rat skin grafts might
preclude their permanent acceptance in animals that are tolerant
of rat lymphohematopoietic antigens by in vitro assays (2).
Nevertheless, the excellent appearanceof most skin grafts at
110 d already exceeds the prolongation that was achieved using
a lethal preparative regimen and mixed xenogeneic BMT in
the same strain combination (1, 2). In addition, the appear-
ance of these skin grafts is much closer to that of normal
skin (including hair growth) than was observed using the
previous lethal preparative regimen.
The delayed appearance ofrat T cells in the PBL of xeno-
geneic marrow recipients prepared with antiThy-1.2 mAb
along with anti-CD4, anti-CD8, 3 Gy WBI and 7 Gy TI,
suggests that thymic seeding by rat stem cells had occurred.
The possibility that rat stem cells engrafted was further sup-
ported by the presence of rat cells in bone marrow and thymus
45 d after BMT (Fig. 3). We cannot, however, rule out the
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